Xeris Biopharma Q1 2026: Net Product Revenue Reaches $67.4 Million

Xeris Biopharma recently released its financial results for the first quarter of 2026, revealing key figures in revenue, expenses, and net loss. The company reported a total revenue of $72.1 million, which includes net product revenue of $67.4 million and license revenue of $4.7 million. Operating expenses reached $79.4 million, and the company’s net loss amounted to $11.9 million, or $0.18 per share.

Specifically, the $67.4 million in net product revenue is broken down into $39.2 million from Recorlev, $24.8 million from Keveyis, and $3.4 million from Xermelo. The $4.7 million in license revenue is attributed to Xeris’s collaboration with Amgen. Furthermore, the $79.4 million in operating expenses consists of $24.8 million in research and development expenses and $54.6 million in selling, general, and administrative expenses. The report indicates that as of March 31, 2026, Xeris Biopharma held cash, cash equivalents, and investments totaling $138.9 million.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI